A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Remco de Brouwer; Wouter P. te Rijdt; Edgar T. Hoorntje; Ahmad Amin; Folkert W. Asselbergs; Moniek G.P.J. Cox; Jeroen F. van der Heijden; Hans Hillege; Jacco C. Karper; Belend Mahmoud; Peter van der Meer; Anton Oomen; Anneline S.J.M. te Riele; Herman H.W. Silljé; Hanno L. Tan; Jan Peter van Tintelen; Dirk J. van Veldhuisen; Berend Daan Westenbrink; Ans C.P. Wiesfeld; Tineke P. Willems; Paul A. van der Zwaag; Arthur A.M. Wilde; Rudolf A. de Boer; Maarten P. van den Berg

doi:10.1093/eurheartj/ehad292

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Remco de Brouwer, Wouter P. te Rijdt, Edgar T. Hoorntje, Ahmad Amin, Folkert W. Asselbergs, Moniek G.P.J. Cox, Jeroen F. van der Heijden, Hans Hillege, Jacco C. Karper, Belend Mahmoud, Peter van der Meer, Anton Oomen, Anneline S.J.M. te Riele, Herman H.W. Silljé, Hanno L. Tan, Jan Peter van Tintelen, Dirk J. van Veldhuisen, Berend Daan Westenbrink, Ans C.P. Wiesfeld, Tineke P. WillemsPaul A. van der Zwaag, Arthur A.M. Wilde, Rudolf A. de Boer^*, Maarten P. van den Berg

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

14 Downloads (Pure)

Abstract

Phospholamban (PLN; p.Arg14del) cardiomyopathy is an inherited disease caused by the pathogenic p.Arg14del variant in the PLN gene. Clinically, it is characterized by malignant ventricular arrhythmias and progressive heart failure.1,2 Cardiac fibrotic tissue remodelling occurs early on in PLN p.Arg14del carriers.3,4 Eplerenone was deemed a treatment candidate because of its beneficial effects on ventricular remodelling and antifibrotic properties.5,6 We conducted the multicentre randomized trial ‘intervention in PHOspholamban RElated CArdiomyopathy STudy’ (i-PHORECAST) to assess whether treatment with eplerenone of asymptomatic PLN p.Arg14del carriers attenuates disease onset and progression.

Original language	English
Pages (from-to)	4284-4287
Number of pages	4
Journal	European Heart Journal
Volume	44
Issue number	40
DOIs	https://doi.org/10.1093/eurheartj/ehad292
Publication status	Published - 21 Oct 2023

Bibliographical note

Access to Document

10.1093/eurheartj/ehad292Licence: CC BY-NC

ehad292Final published version, 229 KBLicence: CC BY-NC

Cite this

de Brouwer, R., te Rijdt, W. P., Hoorntje, E. T., Amin, A., Asselbergs, F. W., Cox, M. G. P. J., van der Heijden, J. F., Hillege, H., Karper, J. C., Mahmoud, B., van der Meer, P., Oomen, A., te Riele, A. S. J. M., Silljé, H. H. W., Tan, H. L., van Tintelen, J. P., van Veldhuisen, D. J., Westenbrink, B. D., Wiesfeld, A. C. P., ... van den Berg, M. P. (2023). A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers. European Heart Journal, 44(40), 4284-4287. https://doi.org/10.1093/eurheartj/ehad292

@article{8c3d1bcb75844cc39b5c4fccd8675d5c,

title = "A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers",

abstract = "Phospholamban (PLN; p.Arg14del) cardiomyopathy is an inherited disease caused by the pathogenic p.Arg14del variant in the PLN gene. Clinically, it is characterized by malignant ventricular arrhythmias and progressive heart failure.1,2 Cardiac fibrotic tissue remodelling occurs early on in PLN p.Arg14del carriers.3,4 Eplerenone was deemed a treatment candidate because of its beneficial effects on ventricular remodelling and antifibrotic properties.5,6 We conducted the multicentre randomized trial {\textquoteleft}intervention in PHOspholamban RElated CArdiomyopathy STudy{\textquoteright} (i-PHORECAST) to assess whether treatment with eplerenone of asymptomatic PLN p.Arg14del carriers attenuates disease onset and progression.",

author = "{de Brouwer}, Remco and {te Rijdt}, {Wouter P.} and Hoorntje, {Edgar T.} and Ahmad Amin and Asselbergs, {Folkert W.} and Cox, {Moniek G.P.J.} and {van der Heijden}, {Jeroen F.} and Hans Hillege and Karper, {Jacco C.} and Belend Mahmoud and {van der Meer}, Peter and Anton Oomen and {te Riele}, {Anneline S.J.M.} and Sillj{\'e}, {Herman H.W.} and Tan, {Hanno L.} and {van Tintelen}, {Jan Peter} and {van Veldhuisen}, {Dirk J.} and Westenbrink, {Berend Daan} and Wiesfeld, {Ans C.P.} and Willems, {Tineke P.} and {van der Zwaag}, {Paul A.} and Wilde, {Arthur A.M.} and {de Boer}, {Rudolf A.} and {van den Berg}, {Maarten P.}",

note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.",

year = "2023",

month = oct,

day = "21",

doi = "10.1093/eurheartj/ehad292",

language = "English",

volume = "44",

pages = "4284--4287",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "40",

}

de Brouwer, R, te Rijdt, WP, Hoorntje, ET, Amin, A, Asselbergs, FW, Cox, MGPJ, van der Heijden, JF, Hillege, H, Karper, JC, Mahmoud, B, van der Meer, P, Oomen, A, te Riele, ASJM, Silljé, HHW, Tan, HL, van Tintelen, JP, van Veldhuisen, DJ, Westenbrink, BD, Wiesfeld, ACP, Willems, TP, van der Zwaag, PA, Wilde, AAM, de Boer, RA & van den Berg, MP 2023, 'A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers', European Heart Journal, vol. 44, no. 40, pp. 4284-4287. https://doi.org/10.1093/eurheartj/ehad292

TY - JOUR

T1 - A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

AU - de Brouwer, Remco

AU - te Rijdt, Wouter P.

AU - Hoorntje, Edgar T.

AU - Amin, Ahmad

AU - Asselbergs, Folkert W.

AU - Cox, Moniek G.P.J.

AU - van der Heijden, Jeroen F.

AU - Hillege, Hans

AU - Karper, Jacco C.

AU - Mahmoud, Belend

AU - van der Meer, Peter

AU - Oomen, Anton

AU - te Riele, Anneline S.J.M.

AU - Silljé, Herman H.W.

AU - Tan, Hanno L.

AU - van Tintelen, Jan Peter

AU - van Veldhuisen, Dirk J.

AU - Westenbrink, Berend Daan

AU - Wiesfeld, Ans C.P.

AU - Willems, Tineke P.

AU - van der Zwaag, Paul A.

AU - Wilde, Arthur A.M.

AU - de Boer, Rudolf A.

AU - van den Berg, Maarten P.

PY - 2023/10/21

Y1 - 2023/10/21

N2 - Phospholamban (PLN; p.Arg14del) cardiomyopathy is an inherited disease caused by the pathogenic p.Arg14del variant in the PLN gene. Clinically, it is characterized by malignant ventricular arrhythmias and progressive heart failure.1,2 Cardiac fibrotic tissue remodelling occurs early on in PLN p.Arg14del carriers.3,4 Eplerenone was deemed a treatment candidate because of its beneficial effects on ventricular remodelling and antifibrotic properties.5,6 We conducted the multicentre randomized trial ‘intervention in PHOspholamban RElated CArdiomyopathy STudy’ (i-PHORECAST) to assess whether treatment with eplerenone of asymptomatic PLN p.Arg14del carriers attenuates disease onset and progression.

AB - Phospholamban (PLN; p.Arg14del) cardiomyopathy is an inherited disease caused by the pathogenic p.Arg14del variant in the PLN gene. Clinically, it is characterized by malignant ventricular arrhythmias and progressive heart failure.1,2 Cardiac fibrotic tissue remodelling occurs early on in PLN p.Arg14del carriers.3,4 Eplerenone was deemed a treatment candidate because of its beneficial effects on ventricular remodelling and antifibrotic properties.5,6 We conducted the multicentre randomized trial ‘intervention in PHOspholamban RElated CArdiomyopathy STudy’ (i-PHORECAST) to assess whether treatment with eplerenone of asymptomatic PLN p.Arg14del carriers attenuates disease onset and progression.

UR - http://www.scopus.com/inward/record.url?scp=85166020798&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehad292

DO - 10.1093/eurheartj/ehad292

M3 - Article

C2 - 37210081

AN - SCOPUS:85166020798

SN - 0195-668X

VL - 44

SP - 4284

EP - 4287

JO - European Heart Journal

JF - European Heart Journal

IS - 40

ER -

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this